Neurology

CLINICAL CASES IN MS: A 24 Y.O. WOMAN WITH PARESTHESIAE AND NON-ENHANCING LESIONS

 

Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.

R.M. is a 24-year-old woman who works at a daycare centre. She is referred from the emergency room because of a two-week history of paresthesiae in both legs and the mid and lower trunk. She is not aware of any weakness. There is no bladder disturbance. She has a subjective mid truncal sensory level. Prior history includes a Bell’s palsy three years ago which was painless and resolved without treatment in 3-4 weeks. Read More

UPCOMING NEUROSENS WEBINAR – MAY 6, 2025

 

Join us for the next event in the NeuroSens Webinar Series:

EPILEPSY MANAGEMENT 2025:  USE OF ADJUNCTIVE THERAPIES IN PRACTICE
Tuesday, May 6th, 2025 – 7:00-8:00 PM EDT

Guest speaker, Dr. Pavel Klein will review the optimal use of adjunctive antiseizure medications in the management of focal epilepsy and provides a practical guide on dose adjustments of concomitant treatments.

CLICK HERE TO REGISTER
or email Kate Stella at kast@lind-pub.com

Dr. Pavel Klein is Director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland and Clinical Professor of Neurology at The George Washington University, Washington, DC. A graduate of Cambridge University, UK, Dr. Klein is the former Director of the Epilepsy Center, the Clinical Neurophysiology Laboratory and of the Neuroendocrinology Unit at Georgetown University Hospital. His research interests include novel pharmacologic and dietary treatments for epilepsy, and epilepsy prevention following traumatic brain injury.

WHO SHOULD ATTEND: General and specialist Canadian neurologists with an interest in epilepsy.

 

AAN DAILY HIGHLIGHTS – WEDNESDAY, APRIL 9, 2025

 

Tuesday Edition
Monday Edition

The following summarizes some of the highlights from Day 3 of the American Academy of Neurology annual meeting (AAN), San Diego, CA, April 5-9, 2025.

MS risk with head trauma
Efficacy of first-line ofatumumab in patients without highly active disease
Semaglutide may reduce MS progression
Higher MS risk with earlier menarche
Biomarker dynamics after DMT initiation
Clinical tip of the day

Read More